Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers

Phase 1

Brief Summary: GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare pharmacokinetics, safety and tolerability of different formulations (tablets and capsules) and dosage (50 and 200mg) of GNS561 after single oral administration in first part and to evaluate the food effect on pharmacokinetics in second part.

Recruitment & Eligibility

Inclusion Criteria

BMI will be between 18 (inclusive) and 26 kg/m² (inclusive).
Participants must be in good general health, with no significant medical history, have no clinically significant (CS) abnormalities on physical examination, vital signs, and 12-lead ECG at Screening and/or before administration of the first dose of study drug
Have a Fridericia's correction factor for QT (QTcF) ≤ 450 ms for male participants and ≤ 470 ms for female participants on 12-lead ECG
Women subjects of childbearing potential must have a negative serum/urine pregnancy test at screening and baseline
Women subjects of childbearing potential and male subjects must agree to use adequate highly effective contraception for the duration of study participation and up to 6 months following completion of therapy
Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Able to understand and provide written informed consent.

Exclusion Criteria

Pregnant or breast-feeding mothers
Known allergic reaction to quinolone derivatives (e.g., quinine, choloroquine, mefloquine)
Subjects with any clinically significant laboratory abnormality
History of QT prolongation (QTc ≥ 500 ms) or family history of long QT arrythmia or cardiac disease or bradycardia < 50/mn or uncorrected hypokalemia
On going uncontrolled infection disease
History of pre-existing retinopathy or maculopathy
Participation in any investigational clinical investigation ≤ 4 weeks prior to first planned dose of GNS561
Malabsorption issues (e.g., gastric bypass or gastrectomy patients), current or history significant gastrointestinal diseases
Patient with a mental or legal disability

Arm && Interventions

Group	Intervention	Description
Part 1 Cohort 1	GNS561 oral tablets and capsules	Three (3) Healthy volunteers, each receiving a single oral dose (50mg) of GNS561 tablets and capsules, after a high fat meal and with a wash-out period of seven days.
Part 1 Cohort 2	GNS561 oral tablets and capsules	Six (6) healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets and capsules, after a high fat meal and with a wash-out period of fourteen days.
Part 2	GNS561 oral tablets and capsules	Nine (9) healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets or capsules (according results of Part 1), in fed condition then in fasting condition, after a wash-out period of fourteen days. Nine (9) other healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets or capsules (according results of Part 1), in fasting condition then in fed condition, after a wash-out period of fourteen days.

Primary Outcome Measures

Name	Time	Method
Incidence of Treatment-Emergent Adverse Events	from first administration until 29 days	adverse events
Maximum Plasma Concentration (Cmax)	Day 1, Day 2, Day 3, Day 4 and Day 7	blood samples at different time from GNS561 administration

Secondary Outcome Measures

Name	Time	Method
Maximum Plasma Concentration (Cmax)	Day 1, Day 2, Day 3, Day 4 and Day 7	blood samples at different time from GNS561 administration

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial